NCT04423159View on ClinicalTrials.gov

Immunological Characteristics of a Population at Risk of Cholera After Oral Cholera Vaccine (CHOVAXIM)

NACompletedINTERVENTIONAL
Enrollment

225

Participants

Timeline

Start Date

October 16, 2016

Primary Completion Date

October 31, 2020

Study Completion Date

October 31, 2020

Conditions
Diarrhea Infectious
Interventions
BIOLOGICAL

OCV Vaccine

2 doses of OCV were administered to all enrolled participants 1st dose administered at baseline and second dose administered 28 days post 1st dose.

Trial Locations (1)

10101

Waya clinic, Kabwe

All Listed Sponsors
collaborator

Johns Hopkins University

OTHER

collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP)

OTHER_GOV

lead

Centre for Infectious Disease Research in Zambia

OTHER

NCT04423159 - Immunological Characteristics of a Population at Risk of Cholera After Oral Cholera Vaccine (CHOVAXIM) | Biotech Hunter | Biotech Hunter